Advertisement

Advertisement

BIOA Stock Latest News

Shrader Reiterates Buy on BioAge, Citing Differentiated NLRP3 Strategy and Attractive Valuation with Unchanged $40 Price Target

RatingsShrader Reiterates Buy on BioAge, Citing Differentiated NLRP3 Strategy and Attractive Valuation with Unchanged $40 Price Target

Monte Rosa, BioAge sink following Novo Nordisk’s ZEUS setback

PremiumThe Fly

Monte Rosa, BioAge sink following Novo Nordisk’s ZEUS setback

5d ago

BioAge Labs price target lowered to $25 from $36 at Roth Capital

PremiumThe Fly

BioAge Labs price target lowered to $25 from $36 at Roth Capital

5d ago

BioAge Therapeutics: Buy Rating Maintained Despite Cut in Price Target to $21 on Refined ASCVD and Ocular Program Assumptions

PremiumRatings

BioAge Therapeutics: Buy Rating Maintained Despite Cut in Price Target to $21 on Refined ASCVD and Ocular Program Assumptions

5d ago

Buy Rating Reaffirmed on BioAge: Sell-Off Seen as Overdone Amid Validated NLRP3 Platform and Triple-Digit Upside Potential

PremiumRatings

Buy Rating Reaffirmed on BioAge: Sell-Off Seen as Overdone Amid Validated NLRP3 Platform and Triple-Digit Upside Potential

5d ago

BioAge Labs pullback after ZEUS data ‘seems overdone,’ says Citi

PremiumThe FlyBioAge Labs pullback after ZEUS data ‘seems overdone,’ says Citi

5d ago

BioAge Labs price target lowered at Jefferies after Novo trial miss

The Fly

BioAge Labs price target lowered at Jefferies after Novo trial miss

5d ago

BioAge Labs price target lowered to $50 from $60 at Oppenheimer

The Fly

BioAge Labs price target lowered to $50 from $60 at Oppenheimer

5d ago

BioAge Labs: Buy Rating Reiterated on NLRP3 Pathway Validation Potential; $50 Price Target Maintained

PremiumRatings

BioAge Labs: Buy Rating Reiterated on NLRP3 Pathway Validation Potential; $50 Price Target Maintained

27d ago

BioAge Moves BGE-102 Into Mid-Stage Obesity Heart-Risk Trial, Raising New Investor Focus

PremiumCompany Announcements

BioAge Moves BGE-102 Into Mid-Stage Obesity Heart-Risk Trial, Raising New Investor Focus

2M ago

BioAge Labs doses first participant in QUELL-CV trial of BGE-102

PremiumThe Fly

BioAge Labs doses first participant in QUELL-CV trial of BGE-102

2M ago

BioAge Labs Shareholders Reelect Directors, Ratify Auditor

PremiumCompany Announcements

BioAge Labs Shareholders Reelect Directors, Ratify Auditor

2M ago

BioAge Labs initiated with a Buy at Roth Capital

PremiumThe FlyBioAge Labs initiated with a Buy at Roth Capital

2M ago

AMD, Under Armour downgraded: Wall Street’s top analyst calls

The Fly

AMD, Under Armour downgraded: Wall Street’s top analyst calls

3M ago

BioAge Labs initiated with a Buy at BTIG

The Fly

BioAge Labs initiated with a Buy at BTIG

3M ago

BioAge Labs: Analyst Reiterates Buy on Best-in-Class Potential of Lead NLRP3 Inhibitor BGE-102 After Encouraging Phase 1/2 Data

PremiumRatings

BioAge Labs: Analyst Reiterates Buy on Best-in-Class Potential of Lead NLRP3 Inhibitor BGE-102 After Encouraging Phase 1/2 Data

3M ago

BioAge Labs reports Q1 EPS (52c), consensus (63c)

PremiumThe Fly

BioAge Labs reports Q1 EPS (52c), consensus (63c)

3M ago

BioAge Labs (BIOA): Phase 1 BGE-102 Data Reinforce Best-in-Class NLRP3 Potential and De-Risk 2026 Cardiovascular Phase 2, Supporting Buy Rating

PremiumRatings

BioAge Labs (BIOA): Phase 1 BGE-102 Data Reinforce Best-in-Class NLRP3 Potential and De-Risk 2026 Cardiovascular Phase 2, Supporting Buy Rating

4M ago

BioAge Labs reports results for Phase 1 trial of BGE-102, to initiate Phase 2

PremiumThe Fly

BioAge Labs reports results for Phase 1 trial of BGE-102, to initiate Phase 2

4M ago

BioAge Labs initiated with a Buy at Needham

PremiumThe FlyBioAge Labs initiated with a Buy at Needham

4M ago

BioAge Labs: Early-Stage Promise in APJ Agonists Balanced by Execution Risk Supports Hold Rating

Ratings

BioAge Labs: Early-Stage Promise in APJ Agonists Balanced by Execution Risk Supports Hold Rating

4M ago

BioAge Labs files automatic mixed securities shelf

The Fly

BioAge Labs files automatic mixed securities shelf

4M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >